Ocular Therapeutix Inc (OCUL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.37B
Last updated: Nov 17, 2026 at 4:15 PM ET
Ocular Therapeutix Inc (OCUL) Statistics
Ocular Therapeutix (OCUL) has a market cap of $1.37B and an enterprise value of $909.26M. It kept -648.64% of revenue as net income over the last 12 months. Its share count is up 22.62% from a year earlier.
Total Valuation
Enterprise value is 33.45% below the market cap, as cash exceeds debt.
| Market Cap | $1.37B |
|---|---|
| Enterprise Value | $909.26M |
| Latest price (Nov 17, 2026) | $6.02 |
Key Dates
The next earnings report is expected on Feb 3, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 3, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 9, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 26.9x and 3.1x. Its year-end P/S ranged from 4.3x to 110.1x from 2016 to 2025.
| P/S Ratio | 26.9x |
|---|---|
| Forward P/S | 26.8x |
| P/B Ratio | 3.1x |
Price Statistics
The stock is down 46.73% over 52 weeks and trades 22.72% below its 50-day average.
| Beta (1Y) | 1.43 |
|---|---|
| 52-Week Change | -46.73% |
| 1-Month Change | -4.29% |
| 3-Month Change | -48.68% |
| 6-Month Change | -24.66% |
| 5-Year Change | +4.97% |
| 10-Year Change | +23.14% |
| Total Return (1Y) | -46.73% |
| Total Return (3Y CAGR) | +38.20% |
| Total Return (5Y CAGR) | -2.15% |
| Return vs SPY (1Y) | -60.37% |
| Max Drawdown (1Y) | -62.69% |
| Max Drawdown (3Y) | -62.69% |
| Sharpe Ratio (1Y) | -0.89 |
| Correlation with SPY (1Y) | 0.26 |
| 50-Day Average | $7.79 |
| 200-Day Average | $8.87 |
| 52-Week Range | $5.94 to $16.44 |
| RSI (14 Days) | 35.7 |
| Average Volume (20 Days) | 2.71M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 9.12x current liabilities, and total debt is 0.17x shareholder equity.
| Current Ratio | 9.12x |
|---|---|
| Quick Ratio | 9.05x |
| Debt / Equity | 0.17x |
| Interest Coverage | -30.26x |
Returns and Efficiency
Return on invested capital is -52.12% over the last 12 months, against a 5-year average of -29.67%.
| Return on Equity (ROE) | -74.12% |
|---|---|
| Return on Assets (ROA) | -53.96% |
| Return on Invested Capital (ROIC) | -52.12% |
| ROE (5Y Average) | -79.77% |
| ROA (5Y Average) | -31.60% |
| ROIC (5Y Average) | -29.67% |
| Asset Turnover | 0.10x |
| Inventory Turnover | 1.58x |
| Receivables Turnover | 1.63x |
| Cash Conversion Cycle | 90 days |
Scores
OCUL has an Altman Z-Score of 0.91, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 0.91 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $50.38M over the last 12 months is down 9.68% from the 12 months before.
| Revenue | $50.38M |
|---|---|
| Revenue Growth (YoY) | -9.68% |
| Gross Profit | $43.99M |
| Operating Income | -$343.07M |
| Pretax Income | -$326.84M |
| Net Income | -$326.81M |
| Reported EPS (TTM) | -$1.46 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 72.81% of the $605.65M in total assets.
| Cash and Equivalents | $530.61M |
|---|---|
| Total Debt | $73.53M |
| Net Cash | $457.08M |
| Net Cash Per Share | $2.03 |
| Working Capital | $511.58M |
| Shareholder Equity | $440.95M |
| Book Value Per Share | $1.96 |
| Total Assets | $605.65M |
| Total Liabilities | $164.70M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $13.90M of capital spending, operating cash flow left -$267.04M of free cash flow.
| Operating Cash Flow | -$253.14M |
|---|---|
| Capital Expenditures | $13.90M |
| Free Cash Flow | -$267.04M |
| FCF Per Share | -$1.22 |
| Depreciation and Amortization | $9.95M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -680.91%.
| Gross Margin | 87.32% |
|---|---|
| Operating Margin | -680.91% |
| Pretax Margin | -648.70% |
| Net Margin | -648.64% |
| FCF Margin | -530.00% |
| Gross Margin (5Y Average) | 90.11% |
Growth
Revenue grew 0.29% a year over 3 years.
| Revenue Growth (3Y CAGR) | +0.29% |
|---|---|
| Revenue Growth (5Y CAGR) | +24.45% |
| Book Value Per Share Growth (2Y CAGR) | +87.20% |
| Tangible Book Per Share Growth (2Y CAGR) | +87.20% |
Dividends and Yields
OCUL does not pay a dividend. Its free cash flow yield is -19.67%.
| FCF Yield | -19.67% |
|---|---|
| Buyback Yield | -0.06% |
| Shareholder Yield | -0.06% |
Peer Position
Against 6 similar companies, OCUL has the 3rd highest P/S.
P/S RatioPeer median 19.1x
ROICPeer median -51.14%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -99.31%
| P/S Ratio | 26.9x vs 19.1x median |
|---|---|
| ROIC | -52.12% vs -51.14% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -9.68% vs -99.31% median |
Analyst Forecast
Consensus estimates put revenue growth at 32.48% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +32.48% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About OCUL
What is OCUL's market cap?
Ocular Therapeutix has a market cap of $1.37B. Its enterprise value, which adds debt and subtracts cash, is $909.26M.
How many shares of OCUL are outstanding?
Ocular Therapeutix has 225.52M shares outstanding. The count is up 22.62% from a year earlier.
Does OCUL pay a dividend?
No. Ocular Therapeutix does not pay a dividend.
How much debt does OCUL have?
Ocular Therapeutix has $73.53M of total debt and $530.61M of cash and equivalents, a net cash position of $457.08M.
OCUL pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors